Anzeige
Mehr »
Login
Sonntag, 28.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Fokus auf Nurexone: High-Level Biotech im Pennystock-Kleid!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
7 Leser
Artikel bewerten:
(0)

Kensey Nash Corporation Announces the Addition of Donald Morel, Jr., Ph.D. to Its Board of Directors

EXTON, Pa., March 22 /PRNewswire-FirstCall/ -- Kensey Nash Corporation today announced that Donald E. Morel, Jr., Ph.D., Chairman and Chief Executive Officer of West Pharmaceutical Services, Inc., has joined Kensey Nash's Board of Directors.

Dr. Morel has served as Chief Executive Officer of West Pharmaceutical Services, Inc. since April 2002 and Chairman of the Board since March 2003. He joined West in 1992 as Director of Research and Development and was promoted to Vice President R&D in 1993. In this role, Dr. Morel spearheaded West's efforts to develop novel and proprietary drug delivery technologies. From 1998 to 2001, he served as President of several of West's divisions and in April 2001 Dr. Morel became President and Chief Operating Officer.

Prior to joining West Pharmaceutical, Dr. Morel developed and managed a broad range of programs involving advanced materials for aerospace, biomedical and pharmaceutical applications for several companies. Dr. Morel holds a BS degree in Engineering from Lafayette College, an MS in Materials Science and a Ph.D. in Materials Science and Veterinary Medicine from Cornell University. He has received several awards and honors including becoming a fellow for the American Institute for Medical & Biologic Engineering. In addition to Kensey Nash's Board, Dr. Morel serves as a Director and Trustee of numerous non-profit organizations including the Fox Chase Cancer Center.

"Dr. Morel's extensive business experience and materials science knowledge will be a tremendous asset to our Board and our company," commented Joseph W. Kaufmann, President and CEO of Kensey Nash Corporation. "His outstanding leadership as Chairman and CEO of West Pharmaceutical is well documented and we are fortunate to have someone of his stature on our Board. I am very pleased to welcome him as a member," he concluded.

"Over the past twenty-five years Kensey Nash has developed a broad range of innovative products and materials that have benefited patients worldwide. I am pleased to have the opportunity to join the Board and look forward to working with the current Directors and talented management team to achieve the company's strategic objectives," Dr. Morel commented.

About Kensey Nash Corporation. Kensey Nash Corporation is a medical device company primarily focused on regenerative medicine utilizing its proprietary collagen and synthetic polymer technology. The Company is recognized as a leader for innovative product development and unique technology in the field of resorbable biomaterials. The Company has an extensive range of products, which are sold through strategic partners in multiple medical markets, including, the cardiology, orthopedic, sports medicine, spine, endovascular and general surgery markets.

Kensey Nash Corporation

CONTACT: Joseph W. Kaufmann, President and Chief Executive Officer of
Kensey Nash Corporation, +1-484-713-2100

Web Site: http://www.kenseynash.com/

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2010 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.